Navigation Links
NIAID funds clinical trials that address the problem of antimicrobial resistance
Date:9/2/2009

Scientists are addressing the threat of antimicrobial drug resistance by launching two new clinical trials aimed at prolonging the effectiveness of currently available antibacterial drugs. The concept underlying both studies: Less is more.

The six-year contracts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, are part of an initiative intended to help answer key questions about proper antimicrobial doses, treatment duration and whether antimicrobial treatment is necessary in all cases. NIAID has made an initial award of $1.5 million to the Children's Hospital of Philadelphia with further funding of up to a total of $13.8 million available over the six-year course of the contract if clinical trial milestones are met. Duke University, Durham, N.C., has received an initial award of $1.4 million. If milestones are met, the total award from NIAID to the Duke team could total up to $11 million over six years.

Many infectious diseases are increasingly difficult to treat because bacteria and other microbes have developed resistance to commonly used antimicrobial drugs. Microbial drug resistance is driven by a variety of forces, including expanded use of antimicrobial drugs in human and animal healthcare. According to one estimate, between 5 and 10 percent of all hospitalized patients in the United States develop a drug-resistant infection of some kind, leading to an added $5 billion in annual healthcare costs.

"The clinical trials supported by this important initiative will provide vital information on the optimal use of antimicrobial drugs in a variety of clinical settings," says NIAID Director Anthony S. Fauci, M.D. "This information is critical to improving patient care and slowing the development of drug resistance."

Reducing the risk of antimicrobial resistance is a priority for NIAID, as exemplified by these new trials and two similar studies now under way. NIAID has also intends to fund additional innovative proposals aimed at slowing the development of antimicrobial resistance through targeted clinical trials. "Historically, development of new antimicrobials has moved at a much slower pace than the evolution of resistance to those treatments, so we need to look at preserving the usefulness of the drugs we have," says Dennis M. Dixon, Ph.D., chief of the Bacteriology and Mycology Branch within NIAID's Division of Microbiology and Infectious Diseases. "One way to reduce the risk of resistance, and therefore to preserve antimicrobials, is to reduce unnecessary use of these drugs."

In the new round of research, investigators at Children's Hospital of Philadelphia will study children with urinary tract infections to determine if treatment with antimicrobials can be shortened from the standard length of up to two weeks and still be effective. The study will enroll as many as 1,000 children.

The Duke study also will test the effectiveness of shorter duration of antimicrobial treatment. This project will focus on hospitalized patients who acquire staphylococcal infections in the bloodstream after use of an intravenous catheter. This study could lead to reduced drug exposure in patients with such infections, which in turn lowers the chance that bacteria will develop resistance to the drugs. The conditions studied in these trialsinfections in the urinary tract or the bloodstreamare ones where development of antimicrobial resistance is of particular concern.

Christine Chiou, M.D., is the NIAID program officer overseeing the projects at Children's Hospital of Philadelphia and at Duke. The projects are part of a second round of funding to support research on optimal ways to treat bacterial infections while minimizing development of antimicrobial resistance. The first awards were made in 2007 to the University of California, Los Angeles, and the University of California, San Francisco (http://www3.niaid.nih.gov/news/newsreleases/2007/ca-mrsa_contracts.htm).


'/>"/>

Contact: NIAID Office of Communications
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIAID Awards New Grant to Expand Studies of Peregrines Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
2. NIAID to fund new human immune profiling research centers
3. NIAID media availability: Still searching for predictors of asthma attacks
4. NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates
5. NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine
6. J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases
7. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
8. NIAID honors AIDS activist Martin Delaney
9. NIAID media availability: Seizures following parasitic infection associated with brain swelling
10. NIAID awards contracts to search for protein markers of disease
11. NIAID creates HIV vaccine discovery branch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes ... a mock evacuation of the facility as part of a disaster drill on October ... Hose EMS and Shelton City Emergency Manager, as well as the Connecticut Long ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
Breaking Medicine Technology: